Ramipril

Generic Name
Ramipril
Brand Names
Altace, Altace HCT
Drug Type
Small Molecule
Chemical Formula
C23H32N2O5
CAS Number
87333-19-5
Unique Ingredient Identifier
L35JN3I7SJ
Background

Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

Indication

For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy.

Associated Conditions
Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event
Associated Therapies
-

Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan

First Posted Date
2007-08-16
Last Posted Date
2007-08-16
Lead Sponsor
Università degli Studi dell'Insubria
Target Recruit Count
80
Registration Number
NCT00517322
Locations
🇮🇹

University of Insubria-Department of Clinical Medicine, Varese, Italy

Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

Phase 4
Completed
Conditions
Interventions
First Posted Date
2007-07-17
Last Posted Date
2014-08-27
Lead Sponsor
Pfizer
Target Recruit Count
229
Registration Number
NCT00502242
Locations
🇿🇦

Pfizer Investigational Site, Cape Town, Western Cape, South Africa

To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients

Phase 3
Completed
Conditions
First Posted Date
2007-06-21
Last Posted Date
2009-07-16
Lead Sponsor
Universiti Sains Malaysia
Target Recruit Count
66
Registration Number
NCT00489229
Locations
🇲🇾

School of Medical Sciences, University Sains Malaysai, Kota Bharu, Kelantan, Malaysia

Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension

First Posted Date
2007-05-14
Last Posted Date
2009-09-02
Lead Sponsor
University of Vigo
Target Recruit Count
120
Registration Number
NCT00473174
Locations
🇪🇸

Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor

Phase 3
Completed
Conditions
Interventions
First Posted Date
2007-02-21
Last Posted Date
2010-11-18
Lead Sponsor
Sanofi
Target Recruit Count
60
Registration Number
NCT00437463
Locations
🇭🇰

Sanofi-Aventis, Hong Kong, Hong Kong

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2006-10-19
Last Posted Date
2012-06-11
Lead Sponsor
Pfizer
Target Recruit Count
422
Registration Number
NCT00389519
Locations
🇺🇸

Le Bonheur Children's Hospital, Memphis, Tennessee, United States

🇦🇷

Hospital de Niños "Dr. Ricardo Gutiérrez", Buenos Aires, Argentina

🇦🇷

Hospital General Interzonal "Dr. José Penna", Buenos Aires, Argentina

and more 97 locations

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

First Posted Date
2006-08-24
Last Posted Date
2011-03-25
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
901
Registration Number
NCT00368277
Locations
🇺🇸

Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension

Phase 4
Conditions
First Posted Date
2006-08-18
Last Posted Date
2007-03-09
Lead Sponsor
Pacific Pharmaceuticals
Target Recruit Count
86
Registration Number
NCT00366119
Locations
🇰🇷

Seoul National University Hospital, Seoul, 28 Yeongeon-dong, Jongno-gu, Korea, Republic of

Ramipril - Hypertension

Phase 4
Completed
Conditions
First Posted Date
2006-05-15
Last Posted Date
2013-03-08
Lead Sponsor
Sanofi
Target Recruit Count
1008
Registration Number
NCT00325806
© Copyright 2024. All Rights Reserved by MedPath